Skip to main content
letter
. 2022 Jun 13;88(1):41. doi: 10.5334/aogh.3660

Table 1.

Cohort and case-control studies investigating occupational asbestos exposure and iCCA risk.


TYPE OF STUDY NO OF SUBJECTS WORKERS’ CATEGORY YEARS ASBESTOS EXPOSURE ASSESSMENT CANCER SITE EFFECT MEASURES

Cohort[10] • 4427 workers
• 22135 matched controls
Shipbreaking workers 1975–1989 A panel of seven experts was asked to assess exposure subjectively Liver and Intrahepatic bile ducts HRadj 1.6 (95% CI 1.08-2.36)

Cohort [11] 12578 workers Asbestos-cement workers 1934–2006 Two expert industrial hygienists estimated asbestos exposure based on already collected data, for each plant and period Liver and Intrahepatic bile ducts SMR 0.99 (95% CI 0.81–1.20) (Males)
SMR 0.87 (95% CI 0.42–1.60) (Females)

Case-control [12] • 41 iCCA cases
• 149 controls
All the different occupations of cases and controls were considered 2006–2010 Based on detailed entire job history and calendar periods, assessment of past asbestos exposure (Yes/No) was performed independently by two Occupational Physicians, unaware of case/control status Intrahepatic bile ducts Occupational exposed to asbestos vs not exposed ORadj 4.81 (95% CI 1.73–13.33)

Case-control [13] • 1458 iCCA cases
• 6773 controls
All the different occupations of cases and controls were considered 1971–2005 The exposure to asbestos for each subject was estimated by applying the NOCCA job-exposure matrix (JEM) to the available occupational codes of cases and controls Intrahepatic bile ducts Cumulative exposure
1.0 (reference):0 f/mL × years
OR adj 1.1 (95% CI 0.9-1.3): 0.1–4.9 f/mL × years
OR adj 1.3 (95% CI 0.9-2.1): 5.0–9.9 f/mL × years
OR adj 1.6 (95% CI 1.0-2.5): 10.0–14.9 f/mL × years
OR adj 1.7 (95% CI 1.1-2.6): ≥15.0 f/mL × years

a Estimates from logistic regression models conditioned on matching variables (year of birth, gender and country). Abbreviations: HRadj: adjusted hazard ratio; SMR: standardized mortality ratio; ORadj: adjusted Odds ratio; f/mL: fibers/mL; NOCCA: Nordic Occupational Cancer Study.